tradingkey.logo
tradingkey.logo
検索

Sophia Genetics SA

SOPH
ウォッチリストに追加
4.540USD
-0.090-1.94%
取引時間 ET15分遅れの株価
325.93M時価総額
損失額直近12ヶ月PER

Sophia Genetics SA

4.540
-0.090-1.94%

詳細情報 Sophia Genetics SA 企業名

SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.

Sophia Genetics SAの企業情報

企業コードSOPH
会社名SOPHiA GENETICS SA
上場日Jul 23, 2021
最高経営責任者「CEO」Camblong (Jurgi)
従業員数423
証券種類Ordinary Share
決算期末Jul 23
本社所在地La Piece 12
都市ROLLE
証券取引所NASDAQ OMX - NASDAQ BASIC
Switzerland
郵便番号CH-1180
電話番号41216941060
ウェブサイトhttps://www.sophiagenetics.com/
企業コードSOPH
上場日Jul 23, 2021
最高経営責任者「CEO」Camblong (Jurgi)

Sophia Genetics SAの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
3.02M
+11.25%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
626.80K
+65.37%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
517.79K
+18.11%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
469.35K
+5.44%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
275.24K
+14.89%
Mr. George A. Cardoza
Mr. George A. Cardoza
Chief Financial Officer
Chief Financial Officer
198.05K
+53.82%
Mr. Didier Hirsch
Mr. Didier Hirsch
Non-Executive Independent Director
Non-Executive Independent Director
184.71K
+27.49%
Dr. Philippe Menu, M.D., Ph.D.
Dr. Philippe Menu, M.D., Ph.D.
Chief Medical Officer and Chief Product Officer
Chief Medical Officer and Chief Product Officer
149.29K
+58.79%
Mr. Daan Van Well
Mr. Daan Van Well
Chief Legal and Compliance Officer
Chief Legal and Compliance Officer
--
--
Ms. Manuela Da Silva Valente
Ms. Manuela Da Silva Valente
Chief People Officer
Chief People Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
3.02M
+11.25%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
626.80K
+65.37%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
517.79K
+18.11%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
469.35K
+5.44%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
275.24K
+14.89%
Mr. George A. Cardoza
Mr. George A. Cardoza
Chief Financial Officer
Chief Financial Officer
198.05K
+53.82%

収益内訳

通貨: USD更新時刻: Mon, Apr 6
通貨: USD更新時刻: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
会社から関連データがまだ開示されていません。
地域別USD
会社名
収益
比率
Rest of EMEA
25.65M
33.20%
France
11.32M
14.65%
United States
10.87M
14.07%
Italy
10.80M
13.98%
Spain
6.03M
7.80%
他の
12.60M
16.30%
事業別
地域別
会社から関連データがまだ開示されていません。

株主

更新時刻: 14 hours ago
更新時刻: 14 hours ago
株主統計
種類
株主統計
株主統計
比率
Alychlo NV
9.74%
Generation Investment Management LLP
9.46%
aMoon Fund
7.68%
Akre Capital Management, LLC
5.18%
Balderton Capital (UK) LLP
4.60%
他の
63.35%
株主統計
株主統計
比率
Alychlo NV
9.74%
Generation Investment Management LLP
9.46%
aMoon Fund
7.68%
Akre Capital Management, LLC
5.18%
Balderton Capital (UK) LLP
4.60%
他の
63.35%
種類
株主統計
比率
Investment Advisor/Hedge Fund
16.25%
Venture Capital
12.29%
Family Office
9.79%
Investment Advisor
8.60%
Individual Investor
8.35%
Hedge Fund
0.92%
Bank and Trust
0.37%
Research Firm
0.10%
Pension Fund
0.04%
他の
43.29%

機関投資家保有株

更新時刻: Wed, Apr 1
更新時刻: Wed, Apr 1
報告期間
機関投資家数
保有株式数
比率
変動額
2026Q1
89
27.73M
38.63%
-11.89M
2025Q4
82
26.92M
39.67%
-12.60M
2025Q3
76
26.89M
39.64%
-8.96M
2025Q2
89
36.69M
54.29%
-200.15K
2025Q1
93
36.63M
54.82%
-389.48K
2024Q4
93
32.50M
49.36%
-965.83K
2024Q3
91
34.60M
52.08%
+657.87K
2024Q2
92
32.44M
48.93%
+1.33M
2024Q1
93
31.91M
48.51%
+375.11K
2023Q4
91
30.61M
46.76%
-676.23K
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
Alychlo NV
6.99M
9.76%
--
--
Feb 15, 2026
Generation Investment Management LLP
6.79M
9.47%
--
--
Feb 15, 2026
aMoon Fund
5.51M
7.69%
--
--
Feb 15, 2026
Akre Capital Management, LLC
3.72M
5.19%
--
--
Dec 31, 2025
Balderton Capital (UK) LLP
3.30M
4.61%
-60.64K
-1.80%
Dec 31, 2025
Camblong (Jurgi)
2.68M
3.74%
-4.49K
-0.17%
Mar 19, 2026
Banque Pictet & Cie S.A.
2.21M
3.08%
--
--
Dec 31, 2025
Principal Global Investors (Equity)
1.40M
1.95%
+8.23K
+0.59%
Dec 31, 2025
Alta Wealth Advisors LLC
1.41M
1.97%
--
--
Dec 31, 2025
詳細を見る

関連ETF

更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
iShares Health Innovation Active ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
iShares Health Innovation Active ETF
比率0%
Fidelity Nasdaq Composite Index ETF
比率0%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
KeyAI